Replimune Revenue and Competitors

Boston, MA USA

Location

#3987

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Replimune's estimated annual revenue is currently $17.8M per year.(i)
  • Replimune's estimated revenue per employee is $46,419
  • Replimune's total funding is $87M.
  • Replimune's current valuation is $1.1B. (January 2022)

Employee Data

  • Replimune has 384 Employees.(i)
  • Replimune grew their employee count by 19% last year.

Replimune's People

NameTitleEmail/Phone
1
Founder, President and Chief Research & Development OfficerReveal Email/Phone
2
Chief Manufacturing OfficerReveal Email/Phone
3
CEOReveal Email/Phone
4
QA OfficerReveal Email/Phone
5
VP Global ITReveal Email/Phone
6
VP, CMCReveal Email/Phone
7
SVP Medical AffairsReveal Email/Phone
8
VP FinanceReveal Email/Phone
9
VP Clinical DevelopmentReveal Email/Phone
10
Head, Global Scientific EngagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Replimune?

Replimune is working to advance the science of oncolytic immunotherapy to improve on existing therapies and help treat more patients with a variety of tumor types. Oncolytic immunotherapy uses viruses that have been modified to selectively replicate in and kill tumors. Replimunes' goal is to develop powerful therapies to overcome cancer.

keywords:N/A

$87M

Total Funding

384

Number of Employees

$17.8M

Revenue (est)

19%

Employee Growth %

$1.1B

Valuation

N/A

Accelerator

Replimune News

2022-04-17 - Tumor-Directed Oncolytic Immunotherapies Show Promise in ...

Replimune Group is developing a novel class of tumor-directed oncolytic immunotherapies, according to a press release from the company.

2022-03-30 - Replimune Provides New Clinical Data, Broad Program ...

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the...

2022-03-22 - Replimune to Host Virtual Investor Event on March 30, 2022

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the...

2021-10-01 - Replimune : Announces Presentations at the 2021 Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC) 3 ...

2017-09-10 - Foresite Capital Leads $55M Series B for Replimune

Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing. The proceeds of the financing will primarily be used to generate human proof of concept data for its lead product, RP ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$58.2M388-1%N/A
#2
$107.2M4274%N/A
#3
$168.6M43835%N/A
#4
$83.4M460-4%N/A
#5
$133.1M4841%N/A